About Michael S. Hanna

Accomplished physician-scientist with two decades of experience performing international trials in academia (University of Pennsylvania) and in drug development with major biopharmaceutical firms (Bristol-Myers Squibb, others). Expertise in formulating strategy and leading complex projects across multiple functions/stakeholders while building teams to identify, analyze and address key problems, unlock talent, establish ownership and accountability, align across internal (commercial, medical, development, safety, regulatory) and external (health authorities, academic research, advocacy organizations) groups. Now serving as CMO for Veralox Therapeutics.

> Broad experience in early to late phase research (phases 1-4) in both CV (thrombosis, coronary artery disease, stroke, antiarrhythmic therapy and heart failure) and non-CV indications (oncology, virology and metabolics); in children and adults.
> Currently consulting with multiple sponsors to further phase 2 and phase 3 development programs in acute coronary syndrome, stroke, congestive heart failure, pulmonary hypertension, diabetes and preclinical optimization of candidate compounds (small molecules and biologics).
> Expertise in developing strategies and programs to address key clinical, regulatory and commercial issues. Adept at developing and executing strategic approaches for both internal (pipeline) and external (business development) sources. Led the Eliquis (apixaban) Atrial Fibrillation clinical development program (annual sales in 2018, $9.9B).
> Extensive experience in collaborating and publishing with a broad network of academic colleagues, working in a variety of operational models (in-house, CRO, ARO-led, hybrid).
> Specialized knowledge and experience in evaluating and mitigating safety issues in CV and non-CV compounds, during development and at the time of regulatory filing.
> Dedicated to a culture of developing and mentoring others, while leading by example. Articulate with strong writing, speaking and presentation skills.